| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-07 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.24 | 4e-07 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-07 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-07 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-07 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.16 | 8e-07 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.15 | 9e-07 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-07 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-07 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |